Biomarin Pharmaceutical Inc. and the n-Lorem Foundation have signed a strategic collaboration and global exclusive license agreement to develop a first-in-disease antisense oligonucleotide (ASO) medicine for people with ReNU syndrome, a rare neurodevelopmental condition caused by variants in the RNU4-2 gene.